
Keywords: GVHD; Graft-versus-host disease; HSCT; Hematopoietic stem cell transplantation; MAC; Myeloablative conditioning; NMD; Nonmalignant disease; OS; Overall survival; RIC; Reduced-intensity conditioning; SCD; Sickle cell disease; TRM; Treatment-related mortali